Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Michelson awarded grant to develop mini optical probe

This article was originally published in Clinica

Executive Summary

The UK government’s Technology Strategy Board has awarded Michelson Diagnostics a £25,000 grant. The money will be used to fund a study into the feasibility of miniaturised optical coherence tomography (OCT) probes for cancer diagnosis. The probes are intended to be attached to the Orpington, UK-based firm’s VivoSight multi-beam OCT scanner, which it CE marked for sale in Europe in October. The scanner is designed to provide images of sub-surface tissue at a "far higher" resolution than other imaging modalities, allowing visualisation of the epidermis, dermis and sub-surface blood vessels. Michelson is hoping to advance the product further via development partnerships with firms such as suppliers of miniature components and commercial partners.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT044850

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel